Are cross-species measures of sensorimotor gating useful for the discovery of procognitive cotreatments for schizophrenia?

Prepulse inhibition of startle (PPI), a measure of sensorimotor gating used to identify antipsychotics, is reduced in schizophrenia patients and in rodents treated with dopamine agonists or glutamate antagonists. The National institute of Menial Health (NIMH)-funded Measurement And Treatment Research to improve Cognition in Schizophrenia (MATRICS) program has initiated a new era in the development of procognitive cotreatments in schizophrenia, independently of treating positive symptoms. Although PPI is not a cognitive process per se, such abnormalities in attention may be predictive of or lead to cognitive deficits. Since first-generation antipsychotics block PPI deficits induced by dopamine agonists, this model cannot identify cognitive enhancers for use as cotreatments with antipsychotics, PPI deficits caused by glutamate antagonists, like the exacerbation of symptoms they produce in patients, are insensitive to dopamine antagonists, but reduced by clozapine. Similarly, both PPI and cognitive deficits in schizophrenia patients are insensitive to firstgeneration antipsychotics, but attenuated by clozapine. Hence, treatment-induced reversals of glutamate antagonist effects on PPI may provide animal and human models to identify treatments of cognitive deficits in patients already treated with existing antipsychotics.

[1]  C. Reavill,et al.  Long-term evaluation of isolation-rearing induced prepulse inhibition deficits in rats: an update , 2005, Psychopharmacology.

[2]  W. Fenton,et al.  Measurement and Treatment Research to Improve Cognition in Schizophrenia: NIMH MATRICS initiative to support the development of agents for improving cognition in schizophrenia , 2004, Schizophrenia Research.

[3]  Michael F. Green,et al.  Identification of separable cognitive factors in schizophrenia , 2004, Schizophrenia Research.

[4]  Michael F. Green,et al.  Longitudinal studies of cognition and functional outcome in schizophrenia: implications for MATRICS , 2004, Schizophrenia Research.

[5]  M. Geyer,et al.  Prepulse inhibition of the acoustically evoked startle reflex in patients with an acute schizophrenic psychosis—A longitudinal study , 2004, European Archives of Psychiatry and Clinical Neuroscience.

[6]  Michael F. Green,et al.  Approaching a consensus cognitive battery for clinical trials in schizophrenia: The NIMH-MATRICS conference to select cognitive domains and test criteria , 2004, Biological Psychiatry.

[7]  M. Geyer,et al.  Measurement and treatment research to improve cognition in schizophrenia: neuropharmacological aspects , 2004, Psychopharmacology.

[8]  M. Geyer,et al.  Effect of antipsychotic treatment on the prepulse inhibition deficit of mGluR5 knockout mice , 2004, Psychopharmacology.

[9]  Robert Freedman,et al.  Alpha-7 nicotinic receptor agonists: potential new candidates for the treatment of schizophrenia , 2004, Psychopharmacology.

[10]  M. Geyer,et al.  Animal behavior models of the mechanisms underlying antipsychotic atypicality , 2003, Progress in Neuro-Psychopharmacology and Biological Psychiatry.

[11]  T. Insel,et al.  Breaking the log-jam in treatment development for cognition in schizophrenia: NIMH perspective , 2003, Psychopharmacology.

[12]  M. Geyer,et al.  Deficits in prepulse inhibition and habituation in never-medicated, first-episode schizophrenia , 2003, Biological Psychiatry.

[13]  D. Javitt,et al.  Reversal of phencyclidine-induced prepulse inhibition deficits by clozapine in monkeys , 2003, Psychopharmacology.

[14]  S. Hyman,et al.  What Are the Right Targets for Psychopharmacology? , 2003, Science.

[15]  M. Low,et al.  Differential Effects of Direct and Indirect Dopamine Agonists on Prepulse Inhibition: A Study in D1 and D2 Receptor Knock-Out Mice , 2002, The Journal of Neuroscience.

[16]  T. Sharma,et al.  Effects of typical and atypical antipsychotics on prepulse inhibition in schizophrenia: a critical evaluation of current evidence and directions for future research , 2002, Psychopharmacology.

[17]  Franz X Vollenweider,et al.  A systems model of altered consciousness: integrating natural and drug-induced psychoses , 2001, Brain Research Bulletin.

[18]  William Perry,et al.  Sensorimotor gating deficits in bipolar disorder patients with acute psychotic mania , 2001, Biological Psychiatry.

[19]  T. Sharma,et al.  Normalization of information processing deficits in schizophrenia with clozapine. , 1999, The American journal of psychiatry.

[20]  D L Braff,et al.  Sensorimotor gating and thought disturbance measured in close temporal proximity in schizophrenic patients. , 1999, Archives of general psychiatry.

[21]  R. Freedman,et al.  Alternative phenotypes for the complex genetics of schizophrenia , 1999, Biological Psychiatry.

[22]  A. Malhotra,et al.  Clozapine Blunts N-Methyl-d-Aspartate Antagonist-Induced Psychosis: A Study with Ketamine , 1997, Biological Psychiatry.

[23]  Anil K Malhotra,et al.  Ketamine-Induced Exacerbation of Psychotic Symptoms and Cognitive Impairment in Neuroleptic-Free Schizophrenics , 1997, Neuropsychopharmacology.

[24]  Herbert Weingartner,et al.  NMDA Receptor Function and Human Cognition: The Effects of Ketamine in Healthy Volunteers , 1996, Neuropsychopharmacology.

[25]  Michael F. Green,et al.  What are the functional consequences of neurocognitive deficits in schizophrenia? , 1996, The American journal of psychiatry.

[26]  J. Krystal,et al.  Subanesthetic effects of the noncompetitive NMDA antagonist, ketamine, in humans. Psychotomimetic, perceptual, cognitive, and neuroendocrine responses. , 1994, Archives of general psychiatry.

[27]  N. Swerdlow,et al.  Assessing the validity of an animal model of deficient sensorimotor gating in schizophrenic patients. , 1994, Archives of general psychiatry.

[28]  N. Swerdlow,et al.  Startle response models of sensorimotor gating and habituation deficits in schizophrenia , 1990, Brain Research Bulletin.

[29]  D L Braff,et al.  Sensorimotor gating and schizophrenia. Human and animal model studies. , 1990, Archives of general psychiatry.

[30]  M. Geyer,et al.  Prestimulus effects on human startle reflex in normals and schizophrenics. , 1978, Psychophysiology.

[31]  M. Geyer,et al.  New approaches to measurement and treatment research to improve cognition in schizophrenia. , 2005, Schizophrenia bulletin.

[32]  Michael F. Green,et al.  A summary of the FDA-NIMH-MATRICS workshop on clinical trial design for neurocognitive drugs for schizophrenia. , 2005, Schizophrenia bulletin.

[33]  J. Hagan,et al.  Predicting drug efficacy for cognitive deficits in schizophrenia. , 2005, Schizophrenia bulletin.

[34]  D Hell,et al.  Prepulse inhibition deficits in patients with panic disorder , 2002, Depression and anxiety.

[35]  M. Geyer,et al.  Mouse genetic models for prepulse inhibition: an early review , 2002, Molecular Psychiatry.

[36]  M. Geyer.  50 ANIMAL MODELS RELEVANT TO SCHIZOPHRENIA DISORDERS , 2002 .

[37]  M. Geyer.  33 THE ROLE OF PRECLINICAL MODELS IN THE DEVELOPMENT OF PSYCHOTROPIC DRUGS , 2002 .

[38]  Dennis S. Charney,et al.  Neuropsychopharmacology : The Fifth Generation of Progress , 2002 .

[39]  H. Meltzer,et al.  The effects of clozapine, risperidone, and olanzapine on cognitive function in schizophrenia. , 1999, Schizophrenia bulletin.

[40]  C. A. Morgan,et al.  Preliminary evidence of an association between sensorimotor gating and distractibility in psychosis. , 1996, The Journal of neuropsychiatry and clinical neurosciences.

[41]  M. Geyer,et al.  Startle habituation and sensorimotor gating in schizophrenia and related animal models. , 1987, Schizophrenia bulletin.